Full-Time

Toxicology Research Fellow

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$196k - $294k/yr

+ Bonus + Equity Awards

Expert

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

Hybrid-eligible role allows for up to two days of remote work per week.

Category
Lab & Research
Medical Research
Required Skills
Data Analysis
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Vertex Pharmaceuticals referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Subject matter expertise in toxicology and the design and interpretation of in vivo studies in common preclinical species
  • In-depth knowledge of animal husbandry and animal welfare issues
  • Excellent data processing and statistical skills
  • Excellent written, verbal communications and influencing skills
  • Microsoft Office Suite or equivalent office productivity tools
  • Bachelor’s, Master’s or Doctoral degree in life sciences or chemistry
  • Bachelors degree and 15 years experience or
  • Masters degree and 12 years experience or
  • PhD and 9 years experience
Responsibilities
  • Develops a broad and deep understanding of the disease area, target biology and chemical space for all Research programs at their resident site
  • Independently develops the strategy for early safety assessment and support for multiple programs from target selection to the VXc milestone and aligns with PSA leadership
  • Collaborates with cross-functional and cross-site partners to develop safety strategies tailored to the portfolio at their resident site
  • Acts as a liaison between the project teams and other PSA subfunctions to arrange required studies and profiling assays and communicates results to the project team and site management with appropriate interpretation
  • Works with PSA study monitors to provide scientific oversight of external studies at CROs/partner organizations and communicates significant findings and study events to supervisors and PSA leadership in a timely manner
  • Collaborates closely with the program regulatory toxicologists to ensure a smooth transition into development at the VXc milestone
  • Prepares high quality reports and presentations to clearly communicate study plans and results to peers, management and project teams
  • Keeps up to date with current literature and emerging industry trends in general pharmaceutical toxicology and therapeutics
  • Acts as an opinion leader and mentor to other toxicologists and cross-disciplinary research scientists.
Desired Qualifications
  • DABT certification preferred
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's EU approval expands its cystic fibrosis treatment market.
  • Partnerships with Arbor and Orna enhance Vertex's gene therapy capabilities.
  • Increased rare disease research funding supports Vertex's R&D efforts.

What critics are saying

  • Competition in cystic fibrosis treatments threatens Vertex's market share.
  • High R&D costs and trial delays could strain Vertex's finances.
  • Regulatory challenges may limit Vertex's drug market expansion.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic biotech partnerships.
  • Vertex's innovative cell and gene therapies set it apart in the biotech industry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

BioSpace
Apr 14th, 2025
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Vertex researcher, Paul Negulescu Ph.D., receives the 2025 Canada Gairdner International Award for pioneering Research and discovery of medicines for Cystic Fibrosis.

Biz Owner Daily
Apr 7th, 2025
EU Approves Expanded Label for Vertex Pharmaceuticals' Cystic Fibrosis Treatment

Vertex Pharmaceuticals has received approval from the European Union to broaden the label for its cystic fibrosis treatment.

Slater Sentinel
Mar 23rd, 2025
Stevens Capital Management LP Makes New $829,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stevens Capital Management LP makes new $829,000 investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Investing.com
Mar 20th, 2025
BMO maintains Vertex stock Market Perform rating and $41 target

The reaffirmation of the rating and target came after Vertex held its first analyst day since its initial public offering in 2020.

Stat News
Mar 18th, 2025
Genetics expert is first NIH director to leave under Trump

He will be replaced on an interim basis by Director Ian Smith, a former Vertex Pharmaceuticals executive.